Nyan Win, MD
Internal Medicine · Mansfield, OHNPI 1134187529
Payments from drug & device makers
Across 58 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$178
- Merck$82
- Novo Nordisk$73
- GSK$70
- Pfizer$49
- Novartis$47
- plus $430 from 18 others
What the payments were for
- Food & beverage$929100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $178 |
| Merck | 4 | $82 |
| Novo Nordisk | 5 | $73 |
| GSK | 5 | $70 |
| Pfizer | 3 | $49 |
| Novartis | 2 | $47 |
| Boehringer Ingelheim | 3 | $46 |
| Amgen | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Lilly USA, LLC | 2 | $27 |
| Dexcom, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Amarin Pharma, Inc. | 2 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $10 |
How this compares
$929 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $70,859 |
| JanuviaSitagliptin Phosphate | 66 | $68,090 |
| TrulicityDulaglutide | 39 | $62,431 |
| EliquisApixaban | 59 | $60,277 |
| JardianceEmpagliflozin | 25 | $32,841 |
| LinzessLinaclotide | 37 | $32,549 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 51 | $25,198 |
| MyrbetriqMirabegron | 23 | $20,335 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $20,231 |
| MounjaroTirzepatide | 19 | $19,967 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $16,836 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $13,923 |
| Spiriva RespimatTiotropium Bromide | 23 | $13,401 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $13,327 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $11,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $82 | $84,92585 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $27 | $82,39858 claims |
| PfizerEliquis, Premarin, Paxlovid | $49 | $71,25499 claims |
| Novo NordiskOzempic | $73 | $70,85965 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $46 | $67,65283 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $70 | $38,65470 claims |
| AbbVieLinzess | $178 | $32,54937 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $20,33523 claims |
| Johnson & JohnsonXarelto | $14 | $10,51624 claims |
| AstraZenecaSymbicort | $15 | $2,77513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Mansfield
- David SubichMansfield$533K
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.